tiprankstipranks
Trending News
More News >
Schrodinger (SDGR)
NASDAQ:SDGR
US Market

Schrodinger (SDGR) AI Stock Analysis

Compare
1,985 Followers

Top Page

SD

Schrodinger

(NASDAQ:SDGR)

Rating:59Neutral
Price Target:
$24.00
▲(14.50%Upside)
Schrödinger's overall stock score is moderate, primarily influenced by strong revenue growth and strategic partnerships, despite ongoing net losses and valuation challenges. Technical analysis indicates stable momentum, while financial performance reflects both strengths in margins and weaknesses in profitability.
Positive Factors
Efficacy
SGR-1505 demonstrated a 22% overall response rate for 45 efficacy-evaluable patients across doses, with the strongest response seen in Waldenström macroglobulinemia patients.
Safety Profile
The safety profile of SGR-1505 remained largely consistent and favorable compared to competing treatments, with some adverse events but no severe bilirubin increases.
Negative Factors
Differentiation Challenges
There is skepticism about how SGR-1505 differentiates itself from competing assets, creating pressure on management to execute business development strategies.
Market Sentiment
Shares are down over 10% as concerns arise about bilirubin levels potentially indicating a liver toxicity signal for the MALT1 class.

Schrodinger (SDGR) vs. SPDR S&P 500 ETF (SPY)

Schrodinger Business Overview & Revenue Model

Company DescriptionSchrodinger (SDGR) is a technology company that specializes in computational software solutions for the life sciences and materials science sectors. The company develops advanced molecular simulation software, enabling customers to accelerate their research and development processes, particularly in drug discovery and materials design. Schrodinger's platform helps scientists achieve more accurate predictions of molecular behavior, thereby reducing the need for physical experiments.
How the Company Makes MoneySchrodinger generates revenue through the sale of its software products and licenses. Customers, which include pharmaceutical companies, biotechnology firms, academic institutions, and industrial corporations, pay for access to Schrodinger's computational platform and tools. The company also engages in collaborative projects and partnerships, where it provides its software and expertise in exchange for milestone payments, royalties, or co-development opportunities. Additionally, Schrodinger might participate in equity investments or joint ventures with other companies to further expand its revenue streams.

Schrodinger Key Performance Indicators (KPIs)

Any
Any
Software Products and Services Revenue Breakdown
Software Products and Services Revenue Breakdown
Details revenue from software products and services, offering a view into the company's technological capabilities and market demand for its digital solutions.
Chart InsightsSchrödinger's software revenue has shown notable volatility but surged significantly in Q1 2025, driven by larger customer renewals and strategic collaborations, notably with Novartis. Despite a decline in professional services and lower software gross margins, the company's focus on expanding partnerships and enhancing software capabilities is paying off. Drug discovery revenue also saw a substantial increase, reflecting successful milestone achievements. Overall, Schrödinger's strategic initiatives are translating into robust revenue growth, positioning the company for continued success in 2025.
Data provided by:Main Street Data

Schrodinger Earnings Call Summary

Earnings Call Date:May 07, 2025
(Q1-2025)
|
% Change Since: -11.64%|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment Positive
The earnings call reflected strong revenue growth and strategic progress in partnerships and R&D, particularly in software and drug discovery. However, there were challenges, including a decline in professional services revenue, lower software gross margins, and increased net loss. Despite these issues, the company's overall outlook for 2025 remains positive.
Q1-2025 Updates
Positive Updates
Strong Revenue Growth
Total revenue for Q1 2025 was $59.6 million, a 63% increase compared to Q1 2024. Software revenue increased by 46% to $48.8 million, driven by larger customer renewals and expansions. Drug discovery revenue was $10.7 million, compared to $3.2 million in the previous year.
Strategic Partnerships and Collaborations
The company recognized revenue from its collaboration with Novartis, and expanded other collaborations, contributing to the growth in drug discovery revenue.
Progress in R&D and Clinical Programs
Initial Phase I data for SGR-1505, a MALT1 inhibitor, is expected in mid-June. Other programs, including CDC7 inhibitor SGR-2921 and Wee1/Myt1 co-inhibitor SGR-3515, are progressing well, with data expected later in the year.
Advancement in Software and Predictive Toxicology
The company released a software update with major enhancements and is advancing its predictive toxicology initiative, aiming for a beta release later this year.
Negative Updates
Decline in Professional Services Revenue
Professional services revenue declined by 31% as service contracts from prior periods were completed.
Lower Software Gross Margin
Software gross margin was 72%, down from 76% in Q1 2024, due to changes in revenue mix associated with the Gates grant.
Net Loss Increase
Net loss after taxes was $60 million or $0.82 per share, compared to a net loss of $54.7 million or $0.76 per share in Q1 2024.
Company Guidance
During the call, Schrödinger's management provided several key metrics and guidance for the fiscal year 2025. For Q1 2025, Schrödinger reported a total revenue of $59.6 million, which marks a 63% increase compared to Q1 2024. Software revenue was $48.8 million, reflecting a 46% growth year-over-year, while drug discovery revenue was $10.7 million, significantly up from $3.2 million in Q1 2024, largely due to milestones from collaborative programs and upfront revenue from a Novartis collaboration. The company maintained a strong financial position with a cash and marketable securities balance of $512 million, up from $367 million at the end of December 2024, primarily due to collections from contracts and a payment from Novartis. Schrödinger reiterated its full-year 2025 guidance, expecting software revenue growth between 10% and 15%, drug discovery revenue in the range of $45 million to $50 million, and a full-year software gross margin between 74% and 75%. Operating expense growth is projected to be under 5% for the year, and the company anticipates a significant reduction in cash burn compared to the previous year.

Schrodinger Financial Statement Overview

Summary
Schrödinger's financial statements show strong gross margins and a solid balance sheet with a low leverage ratio. However, consistent net losses and slow revenue growth are concerns. Recent improvements in cash flow are promising, but sustainable profitability is yet to be achieved.
Income Statement
45
Neutral
The income statement shows mixed performance. Gross profit margin remains healthy at 62.6% for TTM (Trailing-Twelve-Months), indicating efficient cost management. However, the company has consistently reported net losses, with a negative net profit margin of -83.4% in TTM. Revenue growth has been slow, with a modest increase of approximately 11% from 2022 to 2024. EBIT and EBITDA margins are negative, reflecting ongoing operational challenges.
Balance Sheet
55
Neutral
The balance sheet reveals a solid equity base with an equity ratio of 50.3% for TTM, suggesting a stable financial structure. The debt-to-equity ratio is manageable at 0.31, indicating a conservative leverage approach. However, return on equity is negative due to net losses, impacting overall profitability.
Cash Flow
60
Neutral
Cash flow analysis shows improvement, with positive free cash flow in the TTM at $22.2 million, compared to negative free cash flow in previous years. The operating cash flow to net income ratio is positive, indicating cash flow generation despite net losses. However, historical negative operating cash flows highlight potential cash flow management issues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue230.49M207.54M216.67M180.96M137.93M108.09M
Gross Profit144.32M132.08M140.69M101.02M65.62M63.47M
EBITDA-188.03M-209.30M-171.90M-142.47M-108.60M-57.26M
Net Income-192.21M-187.12M40.72M-149.19M-101.22M-26.64M
Balance Sheet
Total Assets743.03M823.23M802.96M688.59M756.49M746.26M
Cash, Cash Equivalents and Short-Term Investments500.30M352.12M463.00M451.09M576.48M642.69M
Total Debt116.16M117.83M127.88M116.49M79.87M11.76M
Total Liabilities369.53M401.78M254.40M240.68M199.40M122.24M
Stockholders Equity373.50M421.44M548.56M447.89M557.07M624.01M
Cash Flow
Free Cash Flow22.16M-164.68M-150.14M-127.70M-77.84M14.22M
Operating Cash Flow25.97M-157.37M-136.73M-119.68M-70.67M16.76M
Investing Cash Flow174.39M148.84M193.03M90.02M-16.81M-381.72M
Financing Cash Flow2.53M10.12M9.05M2.11M7.95M541.27M

Schrodinger Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price20.96
Price Trends
50DMA
23.05
Negative
100DMA
22.67
Negative
200DMA
21.42
Negative
Market Momentum
MACD
-0.72
Positive
RSI
43.88
Neutral
STOCH
46.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SDGR, the sentiment is Neutral. The current price of 20.96 is below the 20-day moving average (MA) of 22.13, below the 50-day MA of 23.05, and below the 200-day MA of 21.42, indicating a bearish trend. The MACD of -0.72 indicates Positive momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 46.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SDGR.

Schrodinger Risk Analysis

Schrodinger disclosed 88 risk factors in its most recent earnings report. Schrodinger reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Schrodinger Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
$46.18B59.8914.07%14.78%39.33%
71
Outperform
$1.86B-0.25%9.37%95.72%
SLSLP
67
Neutral
$369.24M51.393.96%1.31%21.49%-31.23%
59
Neutral
$1.54B-43.33%22.29%-32.89%
DHDH
57
Neutral
$588.28M-86.36%-3.04%-152.59%
54
Neutral
$219.87M-60.75%4.66%11.33%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SDGR
Schrodinger
20.96
0.25
1.21%
SLP
Simulations Plus
18.36
-20.47
-52.72%
VEEV
Veeva Systems
282.61
99.15
54.04%
CERT
Certara
11.49
-2.73
-19.20%
SOPH
SOPHiA GENETICS
3.04
-1.56
-33.91%
DH
Definitive Healthcare Corp
4.02
-1.32
-24.72%

Schrodinger Corporate Events

Executive/Board ChangesShareholder Meetings
Schrodinger Announces Board Elections and Approvals
Neutral
Jun 18, 2025

At the 2025 Annual Meeting of Stockholders held on June 18, 2025, Schrödinger, Inc. announced the election of four Class II directors, the approval of executive compensation, and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The election saw Jeffrey Chodakewitz, Michael Lynton, Nancy A. Thornberry, and Bridget van Kralingen appointed to the board for a three-year term. The executive compensation package received approval, and KPMG LLP’s appointment was ratified, indicating continued confidence in the company’s leadership and financial oversight.

The most recent analyst rating on (SDGR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Schrodinger stock, see the SDGR Stock Forecast page.

Executive/Board Changes
Schrödinger Appoints Richie Jain as New CFO
Positive
May 20, 2025

On May 16, 2025, Schrödinger, Inc. appointed Richie Jain as the new Executive Vice President, Chief Financial Officer, and Treasurer, succeeding Geoffrey Porges. Mr. Jain, who previously served as Senior Vice President of Strategic Finance, brings extensive experience from his tenure at Morgan Stanley. His appointment is expected to strengthen the company’s financial leadership and strategic planning capabilities. The transition includes a comprehensive compensation package and stock options, with Dr. Porges remaining as an advisor until June 6, 2025, to ensure a smooth transition.

The most recent analyst rating on (SDGR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Schrodinger stock, see the SDGR Stock Forecast page.

Business Operations and Strategy
Schrödinger Announces Workforce Reduction Amid Restructuring
Negative
May 19, 2025

On May 19, 2025, Schrödinger, Inc. announced a restructuring of its operations aimed at reducing its workforce by approximately 60 employees, which is about 7% of its full-time staff. This move is part of a broader effort to cut costs and improve cash flow, with the company expecting to incur $3 million in restructuring charges within the fiscal year ending December 31, 2025. The restructuring is anticipated to reduce operating expenses by $30 million annually, with half of the savings resulting from the workforce reduction.

The most recent analyst rating on (SDGR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Schrodinger stock, see the SDGR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 13, 2025